Clinical research
Myovant Sciences announced positive data from LIBERTY 1, one of its two Phase III trials of once daily relugolix combination therapy in uterine fibroids. The trial met its primary endpoint and six key secondary endpoints.
The trial showed that the company’s auto-injector administered treatment delivered the same results as a previous trial using a pre-filled syringe.
In its first-quarter financial report, Solid Biosciences updated on its Phase I/II IGNITE DMD clinical trial. The progress was marred by adverse events.
Polarean Imaging plc announces an update regarding the Company’s Phase III Clinical Trials.
The company said that its lead product was creating greater-than anticipated kidney injuries in trial patients.
Almost every week, biopharma companies release results from ongoing clinical trials. Here’s a roundup of some of the top clinical trial news from the previous week.
Cambridge, Mass.-based Moderna announced publication of results from two Phase I clinical trials of mRNA vaccines against two strains of influenza, H10N8 and H7N0. They were both published in the journal Vaccine.
Polyphor announced the decision to temporarily halt enrollment for the pivotal Phase III trials PRISM-MDR and PRISM-UDR evaluating murepavadin in patients with nosocomial pneumonia due to higher than expected acute kidney injury incidences in the murepavadin arm of the PRISM-MDR trial.
Today has been marked by a wide range of life science and biopharma stories. Here’s a broader look at some of the top stories.
The company announced today that the drug failed to meet its primary endpoint in patients with newly diagnosed O6-methylguanine-DNA methyltransferase (MGMT)-unmethylated glioblastoma multiforme (GBM), a type of brain cancer.
PRESS RELEASES